Global Pulmonary Drug Delivery Devices Market is Expected to Reach US$43.05 bn by 2024

Page 1

Pulmonary Drug Delivery Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024 The global pulmonary drug delivery devices market demonstrates a high degree of competition between GlaxoSmithKline Plc, Boehringer Ingelheim GmbH, AstraZeneca Plc, Teva Pharmaceutical Industries Ltd., and Merck & Co. Inc. states a new research report by Transparency Market Research. With the top five players accounting for more than 67%, the market exhibits a largely consolidated structure. Analysts project this market to remain competitive over the forthcoming years, specifically the drug markets for asthma and chronic obstructive pulmonary diseases (COPD), thanks to the robust product pipelines of established drug-makers. According to the research report, the worldwide market for pulmonary drug delivery devices, which stood at US$32.2 bn in 2015, is expected to progress at a CAGR of 3.30% between 2016 and 2024 and reach US$43.05 bn by the end of the forecast period. The application of these devices is higher in the asthma segment and is expected to remain so over the next few years, thanks to the robust pipeline of drugs for the treatment of asthma. An analysis of the geographical presence of the global pulmonary drug delivery devices market has also been presented in this research report. As per the study, Europe, North America, Asia Pacific, Latin America, and the Middle East and Africa are the prime regional markets for


Turn static files into dynamic content formats.

Create a flipbook
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.